Loading clinical trials...
Loading clinical trials...
A Randomized, Open Label, Multiple Dose, Parallel Group Study to Assess the Safety and Pharmacokinetic Comparability of Two VAY736 Drug Products in Patients With Rheumatoid Arthritis
Conditions
Interventions
ianalumab
Locations
2
Germany
Novartis Investigative Site
Berlin, Germany
Novartis Investigative Site
Amman, Jordan
Start Date
December 19, 2018
Primary Completion Date
July 18, 2024
Completion Date
July 18, 2024
Last Updated
December 2, 2025
NCT07484243
NCT06647069
NCT06841562
NCT07268326
NCT07233655
NCT07029555
Lead Sponsor
Novartis Pharmaceuticals
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions